Abstract:Key PointsAcross evolutionary time, inflammatory responses and depressive symptoms were part of an integrated adaptive response to pathogens that facilitated fighting infection, healing wounds and avoiding subsequent pathogen exposure in the pathogen-rich environments in which humans evolved. In the more sanitary environments of the modern world, the relationship between inflammatory pathways and the brain may drive depression and contribute to non-response to antidepressant medication.Increased levels of inflammatory cytokines and induction of their signalling pathways as well as activation of different immune cell subsets has been detected in the brain and peripheral blood of a subgroup of patients with depression. C-reactive protein (CRP), tumour necrosis factor, interleukin-1β (IL-1β) and IL-6 appear to be the most reliably elevated inflammatory markers in the peripheral blood of subjects with depression.Activation of the inflammasome by stress-induced, non-pathogenic stimuli, including damage-associated molecular patterns as well as microbial-associated molecular patterns elaborated from the gut microbiome, may drive peripheral inflammatory responses, which are then transmitted to the brain by trafficking of activated monocytes.Inflammation impacts several neurotransmitter systems in the brain, including serotonin, dopamine and glutamate pathways, as well as the kynurenine pathway, which generates the neurotoxic metabolite quinolinic acid. Neuroimaging studies have demonstrated that disruption of neurotransmitter pathways is associated with inflammation-induced alterations in brain circuits that mediate motivation and motor activity as well as anxiety, arousal and alarm.Activation of effector T cells during stress can prevent the development of depressive- and anxiety-like behaviour in mice. These effects may be mediated by the trafficking of effector T cells to the meningeal space where they produce IL-4, which supports anti-inflammatory responses while also stimulating the production of growth factors in the brain that support neural plasticity and resilience.Studies in depression suggest that inflammatory biomarkers, such as CRP, can be used to enrich samples for anti-inflammatory clinical trials for depression that target inflammation-related symptoms such as anhedonia and anxiety, thereby supporting intelligent trial design. Though still in development, imaging of neuroinflammation will help establish a 'target' in the brain to further facilitate the testing of anti-inflammatory therapies for depression.

Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression.

Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression.

Significantly Increased Expression of T-cell Activation Markers (Interleukin-2 and HLA-DR) in Depression: Further Evidence for an Inflamatory Process During That Illness

Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression.

Major Depression: An Immune-Inflammatory Disorder

Evidence for an immune response in major depression: a review and hypothesis.

Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression

Evidence for an Immune Response in Major Depression: A Review and Hypothesis

The role of inflammation in depression: from evolutionary imperative to modern treatment target

Serotonin-Immune Interactions in Major Depression

Is Depression an Inflammatory Condition? A Review of Available Evidence.

Increased Serum IL-6 and IL-1 Receptor Antagonist Concentrations in Major Depression and Treatment Resistant Depression.

The Psychoneuroimmuno-Pathophysiology Of Cytokine-Induced Depression In Humans

So depression is an inflammatory disease, but where does the inflammation come from?

T Helper-1 Activation Via Interleukin-16 is a Key Phenomenon in the Acute Phase of Severe, First-Episode Major Depressive Disorder and Suicidal Behaviors

Mechanistic Explanations How Cell-Mediated Immune Activation, Inflammation and Oxidative and Nitrosative Stress Pathways and Their Sequels and Concomitants Play a Role in the Pathophysiology of Unipolar Depression

Increased IL-6 trans-signaling in depression: focus on the tryptophan catabolite pathway, melatonin and neuroprogression.

The Role of Inflammation in Depression and Fatigue

From inflammation to sickness and depression: when the immune system subjugates the brain

Immune Disturbances During Major Depression: Upregulated Expression of Interleukin-2 Receptors

Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions